MarginsXMarginsX
Home › Markets › Health Care › APRE

Aprea Therapeutics Inc. (APRE)

APRE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.4063
-2.38% on the day
Market cap
$5.8M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerAPRE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2019
SEC CIK0001781983
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
35.7 months
$37.8M cash at September 30, 2026
Share count, 1 year
+124.9%
2025-11-11 to 2026-11-04 · +279.8% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
$61K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$37.8M cash; operating cash flow -$3.2M a quarter.Report 2026-09-30
Shares outstanding14,191,136 (2026-11-04); 6,310,673 a year earlier; 3,736,673 three years earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months3 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-04-22
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-07-23
AuditorEisnerAmper LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-03-16
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $61K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$4.8M-$3.7M$37.8MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q2 2026
2026-06-30
Not filed-$3.6M-$3.3M$41.2MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q1 2026
2026-03-31
Not filed-$3.3M-$2.8M$46.5MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q4 2025
2025-12-31
Not filed-$2.5M-$3.0M$14.6MNo debt tagsNeeds four quarters10-K 2026-03-16
Q3 2025
2025-09-30
Not filed-$3.0M-$3.2M$13.7MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q2 2025
2025-06-30
Not filed-$3.2M-$3.1M$16.5MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q1 2025
2025-03-31
Not filed-$3.9M-$3.6M$19.3MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q4 2024
2024-12-31
Not filed-$2.9M-$3.5M$22.8MNo debt tagsNeeds four quarters10-K 2026-03-16

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B72026-05-15
Latest annual report10-K2026-03-16
Latest quarterly / interim10-Q2026-11-04
Latest current report
FORM 8-K
8-K2026-11-04
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 446 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-19.7%
1 month-30.7%
3 months-38.0%
Year to date-51.2%
1 year-65.0%
From 52-week high-67.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BLRXBioLineRx Ltd.$1.15-12.61%$5.7M
LTRNLantern Pharma Inc.$0.3890-10.18%$5.8M
ALZNAlzamend Neuro Inc.$1.18-4.84%$5.7M
ACXPAcurx Pharmaceuticals Inc.$0.9350-2.60%$5.7M
FBLGFibroBiologics Inc.$0.9034-2.00%$6.1M
TOVXTheriva Biologics Inc.$0.1400-2.85%$6.4M
ENVBEnveric Biosciences Inc.$1.44-4.95%$6.4M
JAGXJaguar Health Inc.$0.3864-7.74%$5.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier